On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

Completed · Phase 1

Conditions studied: Contraception

In brief

This is an exploratory prospective study investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility.

Key facts

Study ID

NCT03354117

Run by

Stanford University

People needed

12

Starts

2018-03-15

Expected to finish

2019-05-31

Last updated by the study team

2019-06-25

Who can join

Age: 18 and older, up to 38. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women, aged 18-38
• English speaking
• Able to consent, literate
• Access to smart phone throughout study
• History of regular menses
• Documented baseline cycle with ovulation
• Not currently using or needing hormonal contraception
• Not currently using or needing regular NSAIDS
• Able to commit to frequency of study visits

You may not qualify if…

• Currently or recently (<2months) pregnant
• Currently or recent (<2months) breastfeeding
• Current or recent (<2months) use of hormonal medication
• Regular NSAID use
• Known cardiac risk factors (e.g. personal history of obesity, HTN, cardiac disease, diabetes)
• BMI > 30, as some studies have shown decreased efficacy of ulipristal in obese women37
• Allergy or previous unacceptable side effects with study medications

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.